In a report released today, Michael Petusky from Barrington maintained a Buy rating on Orthofix, with a price target of $17.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Michael Petusky has given his Buy rating due to a combination of factors, including Orthofix’s strong financial performance in the second quarter. The company’s revenue of $203.1 million surpassed both the firm’s and the consensus estimates, driven by robust sales in bone growth therapies and global orthopedics. Additionally, Orthofix’s adjusted earnings per share and EBITDA significantly exceeded expectations, reflecting effective expense management and operational efficiency.
Orthofix’s balance sheet remains solid with $68.7 million in cash and restricted cash, alongside a manageable debt level. The company also reaffirmed its financial guidance for 2025, projecting continued revenue growth and positive free cash flow. These positive financial indicators, combined with an increased price target of $17, support Petusky’s optimistic outlook and Buy rating for Orthofix’s stock.
In another report released yesterday, Roth MKM also maintained a Buy rating on the stock with a $22.00 price target.